Administration of PARP‐1 inhibitors (rucaparib and olaparib) to patients with high‐risk neuroblastoma can make cancer cells sensitive to X‐rays, and its mechanism of action is likely to be accumulated DNA damage.51 The gene discussed is PARP1; the disease is cancer.